A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data

被引：13

作者：

Cheah, Chan Y. ^{[1
,2
,3
,4
]}

Tam, Constantine S. ^{[5
,6
]}

Lasica, Masa ^{[7
]}

Verner, Emma ^{[8
,9
]}

Browett, Peter J. ^{[10
]}

Anderson, Mary Ann ^{[11
,12
]}

Hilger, James ^{[13
,14
]}

Fang, Yiqian ^{[13
,14
]}

Simpson, David ^{[13
,14
]}

Opat, Stephen ^{[5
,15
]}

机构：

[1] Univ Western Australia, Med Sch, Crawley, Australia

[2] Sir Charles Gairdner Hosp, Dept Haematol, Nedlands, WA, Australia

[3] Pathwest Lab Med, Nedlands, WA, Australia

[4] Linear Clin Res, Nedlands, WA, Australia

[5] Monash Univ, Clayton, Vic, Australia

[6] Alfred Hosp, Melbourne, Vic, Australia

[7] St Vincents Hosp Melbourne, Fitzroy, Vic, Australia

[8] Concord Repatriat Gen Hosp, Concord, Australia

[9] Univ Sydney, Sydney, NSW, Australia

[10] Auckland City Hosp, Dept Haematol, Auckland, New Zealand

[11] Walter & Eliza Hall Inst Med Res, Div Blood Cells & Blood Canc, Parkville, Vic, Australia

[12] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[13] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China

[14] BeiGene USA Inc, San Mateo, CA USA

[15] Monash Hlth, Clayton, Vic, Australia

来源：

关键词：

D O I：

10.1182/blood-2022-169662

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2321 / 2323

页数：3